- Home
- HGLB vs CGEN Comparison
HGLB vs CGEN Comparison
Compare HGLB & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGLB
- CGEN
- Stock Information
- Founded
- HGLB 1998
- CGEN 1993
- Country
- HGLB United States
- CGEN Israel
- Employees
- HGLB N/A
- CGEN N/A
- Industry
- HGLB Trusts Except Educational Religious and Charitable
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HGLB Finance
- CGEN Health Care
- Exchange
- HGLB Nasdaq
- CGEN Nasdaq
- Market Cap
- HGLB 198.2M
- CGEN 167.4M
- IPO Year
- HGLB N/A
- CGEN 2000
- Fundamental
- Price
- HGLB $8.51
- CGEN $1.43
- Analyst Decision
- HGLB
- CGEN
- Analyst Count
- HGLB 0
- CGEN 0
- Target Price
- HGLB N/A
- CGEN N/A
- AVG Volume (30 Days)
- HGLB 91.8K
- CGEN 217.0K
- Earning Date
- HGLB 01-01-0001
- CGEN 08-06-2025
- Dividend Yield
- HGLB 13.16%
- CGEN N/A
- EPS Growth
- HGLB N/A
- CGEN N/A
- EPS
- HGLB N/A
- CGEN N/A
- Revenue
- HGLB N/A
- CGEN $22,144,000.00
- Revenue This Year
- HGLB N/A
- CGEN N/A
- Revenue Next Year
- HGLB N/A
- CGEN $105.77
- P/E Ratio
- HGLB N/A
- CGEN N/A
- Revenue Growth
- HGLB N/A
- CGEN N/A
- 52 Week Low
- HGLB $6.42
- CGEN $1.13
- 52 Week High
- HGLB $9.45
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- HGLB 56.96
- CGEN 37.47
- Support Level
- HGLB $8.23
- CGEN $1.43
- Resistance Level
- HGLB $8.43
- CGEN $1.53
- Average True Range (ATR)
- HGLB 0.17
- CGEN 0.06
- MACD
- HGLB 0.04
- CGEN 0.00
- Stochastic Oscillator
- HGLB 88.89
- CGEN 44.44
About HGLB Highland Global Allocation Fund
Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.